Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study

Secukinumab, a fully human monoclonal antibody neutralizing interleukin‐17A, has been shown to have significant efficacy in the treatment of moderate to severe psoriasis. Long‐term (3‐year) efficacy and safety of secukinumab in Japanese patients with moderate to severe psoriasis were evaluated in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Yukari, Ohtsuki, Mamitaro, Morita, Akimichi, Yamaguchi, Masako, Shima, Tomohiro, Tani, Yumiko, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590222/
https://www.ncbi.nlm.nih.gov/pubmed/30672623
http://dx.doi.org/10.1111/1346-8138.14761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590222/
https://www.ncbi.nlm.nih.gov/pubmed/30672623
http://dx.doi.org/10.1111/1346-8138.14761

Ejemplares similares